Radiation Oncology Committee Meeting Agenda
Chair: Jeff Bogart
Vice-Chair: Joseph Salama

PRIORITY DISCUSSION:

- PROPOSAL: PHASE I/II TRIAL OF FIVE FRACTION FSRT FOR LARGE BRAIN METASTASES (MELLON)

- PROPOSAL: SBRT POST PROSTATECTOMY (KISHAN)

- PROPOSAL: HYPOFx RT IN ELDERLY WITH GBM (PALMER)

NEAR ACTIVATION

- PHASE III TRIAL OF PCI FOR SMALL CELL LUNG CANCER (SWOG)
- PHASE III TRIAL OF IMMUNOTHERAPY FOR LIMITED SMALL CELL LUNG CANCER (LU 005)

ACTIVE STUDIES

Lung

- AFT- 16: Induction PDL-1 inhibition Stage III NSCLC  
  Urbanic
- AFT-07 Veliparib + ChemoRT Stage III NSCLC  
  Salama
- C 30610: Limited Stage Small Cell Intergroup Trial  
  Bogart
- NRG CC003: PCI with or without Hippocampal Avoidance for SCLC  
  Grecula

Breast

- Alliance A221505 Phase II Randomized Trial of Hypofractionated Post
  Mastectomy Radiation with Breast Reconstruction  
  Poppe
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

NRG Oligometastatic Trials

**CNS**

- CE.7  
  SRS vs WBRT for Multiple Brain Metastases

- A221208  
  Randomized phase II study: Corticosteroids + bevacizumab vs. corticosteroids + placebo (BeSt) for radionecrosis after radiosurgery for brain metastases

- N0577  
  Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant PCV chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low grade glioma (CODEL)

- A071102  
  A phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation

**GI**

- A021501  
  "Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated RT for Borderline Resectable Adenocarcinoma of the Head of the Pancreas"

- N 1048  
  A phase II/III trial of neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision (PROSPECT)

**GU**

- A031701  
  PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (ddGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS (KWOK)

- Prostate Cancer Studies (Chen)
Other

A091605 Stereotactic body radiotherapy and pembrolizumab in advanced merkel cell carcinoma

Chmura

IROC Update